Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies (PTN)
XASE:PTN
Earnings Data
Report Date
May 19, 2026Before Open (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
-1.24Last Year’s EPS
-9Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted substantial strategic and financial progress: a successful $18.2M public offering (net $16.9M), regained NYSE American listing, a $14.5M cash balance with a runway beyond March 31, 2027, and clear IND/Phase I timelines for two MC4R programs with sufficient cash to execute Phase I. Offsetting these positives are materially higher operating expenses and a larger net loss versus the prior year, minimal current commercial revenue, a decline in other income, and remaining uncertainties around warrant exercises and clinical differentiation. On balance, the financing and clear development milestones materially de-risk near-term execution, while the company still faces typical biotech development and competitive risks.Company Guidance
Successful Financing and Strengthened Balance Sheet
Completed an upsized underwritten public offering on November 12, 2025 with gross proceeds of $18.2M and net proceeds of approximately $16.9M; offering included ~2.8M shares/prefunded warrants and Series J/K warrants. The financings restored NYSE American compliance and resumed trading under symbol PTN.
Significant Cash Increase and Extended Runway
Cash and cash equivalents were $14.5M as of December 31, 2025, up from $1.3M at September 30, 2025 (increase of ~1,015%) and $2.6M at June 30, 2025 (increase of ~458%). Management expects cash runway to extend beyond the quarter ending March 31, 2027.
Pipeline Advancement — IND and Phase I Timelines
Lead oral MC4R agonist PL-7737 remains on track for IND submission and initiation of Phase I SAD/MAD in H1 2026. Next-generation once-weekly peptide MC4R agonist targeting IND in H2 2026.
Sufficient Funding to Execute Early Clinical Plan
Company states it has sufficient cash to advance both the oral small molecule and long-acting peptide through Phase I SAD/MAD. Oral small molecule data expected by year-end 2026; long-acting peptide data expected in first half of 2027.
Monetization of Non-Core Asset
Executed sublicensing of PL9643 (MC1R agonist for dry eye disease) to Altanispac Labs in January 2026, resulting in approximately $3.8M in upfront consideration (noncash debt cancellation) and retained potential milestone/royalty upside; $3.8M to be recognized as license revenue in the quarter ending March 31, 2026.
Focused Strategic Positioning in Rare/Genetic Obesity
Clear strategic focus on rare neuroendocrine obesity disorders (hypothalamic obesity and Prader-Willi syndrome) with an emphasis on differentiated product profiles (improved tolerability, reduced GI side effects, minimized off-target hyperpigmentation) and optionality for combination with GLP-1 therapies.
Operational Consistency in Cash Burn
Net cash used in operations was $4.8M for the quarter, consistent with the same quarter last year, indicating predictable near-term operating cash burn.
PTN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PTN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $17.39 | $17.59 | +1.15% |
Nov 13, 2025 | $11.04 | $10.80 | -2.17% |
Oct 07, 2025 | $7.90 | $7.27 | -7.97% |
May 14, 2025 | $4.57 | $5.25 | +14.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Palatin Technologies (PTN) report earnings?
Palatin Technologies (PTN) is schdueled to report earning on May 19, 2026, Before Open (Confirmed).
What is Palatin Technologies (PTN) earnings time?
Palatin Technologies (PTN) earnings time is at May 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTN EPS forecast?
PTN EPS forecast for the fiscal quarter 2026 (Q3) is -1.24.